Avalyn Pharma (NASDAQ:AVLN) Hits New 1-Year Low – Time to Sell?

Avalyn Pharma Inc. (NASDAQ:AVLN) reached a new 52-week low during mid-day trading on Thursday. The company traded as low as $24.14 and last traded at $24.48, with a volume of 285,265 shares traded. The stock had previously closed at $25.53.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Morgan Stanley boosted their price objective on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Wall Street Zen downgraded shares of Avalyn Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Raymond James Financial started coverage on shares of Avalyn Pharma in a research note on Friday, October 2nd. They set an “outperform” rating and a $60.00 target price for the company. Finally, Weiss Ratings began coverage on shares of Avalyn Pharma in a report on Thursday, August 13th. They set a “sell (d+)” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $60.00.

Avalyn Pharma Trading Up 0.2%

The stock has a market cap of $1.14 billion and a price-to-earnings ratio of -1.13. The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 33.12. The company’s fifty day moving average price is $33.25.

Avalyn Pharma (NASDAQ:AVLN) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05. As a group, sell-side analysts predict that Avalyn Pharma Inc. will post -3.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new stake in shares of Avalyn Pharma in the 2nd quarter valued at $1,321,000. State Street Corp acquired a new position in Avalyn Pharma during the second quarter worth $10,501,000. Braidwell LP acquired a new position in Avalyn Pharma during the second quarter worth $26,382,000. Finally, Montanova Capital LLC bought a new position in Avalyn Pharma during the second quarter valued at about $82,402,000.

Avalyn Pharma Company Profile

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company’s primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company’s development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.